Vimarsana
Biggest News Aggregation in the World

Page 2 - Expanded Use Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Expanded Use Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Expanded Use Access Program Today - Breaking & Trending Today

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases - Vimarsana News

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

Published: August 22, 2023

BEDMINSTER, N.J., Aug. 22, 2023 -- Matinas BioPharma , a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery...

Source: marketscreener.com
Related Topics:
United StatesMatinas BiopharmaTheresa MatkovitsDavid BoulwareJody CainNational Institutes Of HealthInfectious Diseases Society Of AmericaNational Institute Of Neurological DisordersNational Resilience IncUniversity Of MinnesotaUniversity Of Minnesota Medical SchoolCompassionate Expanded Use Access ProgramMinnesota Medical SchoolMajor ArticleClinical Infectious DiseasesInfectious Diseases SocietyChief Development OfficerExpanded Use Access ProgramNational InstituteNeurological DisordersNational InstitutesInfectious DiseasesPrivate Securities Litigation Reform ActNational Resilience
Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update - Vimarsana News

Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update

Published: August 9, 2023

FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality...

Source: marketscreener.com
Related Topics:
United StatesNew JerseyJody CainMatinas BiopharmaJeromed JabbourNational Resilience IncNational ResilienceDevelopment AuthorityAccess ProgramEuropean CongressMatina Compassionate Expanded Use ProgramDrug AdministrationPopulation Pathway For AntifungalsOral Amphotericinb ProgramKey Program UpdatesMatinas Biopharma Holdings IncCompany Compassionate Expanded Use Access ProgramSmall Oligonucleotide ProgramBiomedical ResearchCompassionate Use ProgramExpanded Use ProgramNationwide ChildrenChief Executive OfficerLimited Population PathwayExpanded Use Access Program